The study retrospectively analyzed 56 patients with systemic lupus erythematosus (SLE) who received a single dose of obinutuzumab (1000 mg) at Renji Hospital in Shanghai from October 2021 to March 2024, with a follow-up of 48 weeks.[1][2][3] At baseline, 35.7% of patients were newly diagnosed, 57.1% had relapsed/refractory disease, and 7.1% were on maintenance therapy.[2][3] By week 48, 37.5% of patients achieved remission according to DORIS, low disease activity status (LLDAS) in 32.1%, and clinical stability in 19.6%.[2][3] Overall, 69.6% of patients achieved DORIS remission or LLDAS.[1][3] In patients with lupus nephritis, 86.7% achieved a complete renal response by week 48.[1] B-cell counts declined rapidly and began to recover from week 36, the glucocorticoid dose was reduced from a mean of 43.04 ± 18.19 mg/day (range 0–60) to 8.95 ± 9.78 mg/day (range 0–50).[2][3] Obinutuzumab was well tolerated, with infections occurring in 14 cases (25.0%) and infusion reactions in 4 cases (7.1%).[2][3]